What is the evidence level of using bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist for patients with NSTE-ACS undergoing PCI who are at high risk of bleeding?
The evidence level for using bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist for patients with NSTE-ACS undergoing PCI who are at high risk of bleeding is B. This is based on the Level of Evidence B recommendation found in Class IIa of the evidence-based guidelines for Intravenous UFH in patients with NSTE-ACS undergoing PCI. Specifically, the guidelines state that it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist (310,396). 